Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

Some Firms Are Already Localizing

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

China ran a deficit of $3bn in the drug trade with the US in 2024. (Shutterstock)

More from China

More from Focus On Asia